James A. Doecke
Samantha C. Burnham
Victor L. Villemagne
Christopher J. Fowler
Stephanie R. Rainey-Smith, Edith Cowan UniversityFollow
Ralph N. Martins
Colin L. Masters
AIBL Research Group
Alzheimer's Research and Therapy
BioMed Central Ltd
Centre of Excellence for Alzheimer’s Disease Research and Care / School of Medical and Health Sciences
NHMRC Number : APP1105784
Background: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Methods: Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Results: Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic - area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Conclusion: Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials. © 2020 The Author(s).
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Neuroscience and neurorehabilitation